SCHEMBL4828164

SCHEMBL4828164

COc1ccccc1-c1cccc(CNCCCOc2cccc(Nc3cc(C)nc4ccccc34)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
HTT P42858 1/20 0.56
ABCB1 P08183 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
LMNA P02545 2/20 0.45
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
HTR7 P34969 1/20 0.43
SCN8A Q9UQD0 2/20 0.42
ACP1 P24666 3/20 0.42
CD274 Q9NZQ7 1/20 0.42
CASR P41180 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
NPC1 O15118 1/20 0.40
HTR1A P08908 1/20 0.40
BCHE P06276 1/20 0.40
NCF1 P14598 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828030 0.89 TSHR (0.69) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4633382 0.88 TSHR (0.62) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4832314 0.86 TSHR (0.70) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4633373 0.85 TSHR (0.64) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4832182 0.84 TSHR (0.58) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4829830 0.83 TSHR (0.54) TSHRHTTLMNAGAASCN8A
SCHEMBL4832072 0.83 NPC1 (0.50) TSHRHTTABCB1ABCG2LMNA
SCHEMBL14279442 0.82 TSHR (0.70) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4834583 0.81 TSHR (0.61) TSHRHTTABCB1ABCG2LMNA
SCHEMBL4832413 0.81 TSHR (0.66) TSHRHTTABCB1ABCG2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 TSHR 1103/4885HTT 1829/4885ABCB1 812/4885
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 TSHR 1103/4885HTT 1829/4885ABCB1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.